Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615.

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL

Expert Opinion on Therapeutic Patents Pub Date : 2024-10-29 DOI:10.1080/13543776.2024.2423018

Cindy Bandala, Donaciano Flores-Robles, Pavel Sierra-Martínez, Alejandro Millán-Vega, Eunice Ruíz González, Martin Perez-Santos

引用次数: 0

Abstract

Introduction: CD38 and BCMA are proteins expressed at high levels in multiple myeloma cells, so they are targets for the development of mono- or multispecific antibodies.

Areas covered: Patent US20240132615 describes anti-CD3/BCMA/CD38 trispecific antibodies and a method of treating relapsed/refractory multiple myeloma pharmaceutically. In vitro and preclinical results show that anti-CD3/BCMA/CD38 trispecific antibodies have stronger binding affinity and killing potency compared to daratumumab, isatuximab, and teclistamab antibodies.

Expert opinion: The trispecific structure and a silenced Fc are pharmaceutical advantages of the anti-CD3/BCMA/CD38 antibody for the treatment of relapsed or refractory multiple myeloma.

查看原文本刊更多论文

用于多发性骨髓瘤的三特异性抗 CD3/BCMA/CD38 抗体：US20240132615 的专利评估。

简介：CD38和BCMA是多发性骨髓瘤细胞中高水平表达的蛋白，因此它们是开发单特异性或多特异性抗体的靶点。专利US20240132615描述了抗CD3/BCMA/CD38三特异性抗体和一种治疗复发/难治性多发性骨髓瘤的药物方法。体外和临床前研究结果表明，抗CD3/BCMA/CD38三特异性抗体与daratumumab、isatuximab和teclistamab抗体相比，具有更强的结合亲和力和杀伤力。专家观点：三特异性结构和沉默的Fc是抗CD3/BCMA/CD38抗体治疗复发或难治性多发性骨髓瘤的药物优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Therapeutic Patents 医学-药学

CiteScore

12.10

自引率

1.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Therapeutic Patents (ISSN 1354-3776 [print], 1744-7674 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days.